Upstream Bio, Inc.
UPB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002022626
In the last 90 days, Upstream Bio, Inc. insiders filed 0 open-market purchases and 5 sales; 148 institutions reported holding it in 13F filings for Q2 2026, worth $350.1M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Upstream Bio, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 95 | 133 | +38 |
| Shares | 44.5M | 51.2M | +6.71M (+15.1%) |
| Value | $836.3M | $1.39B | +$553.1M (+66.1%) |
New holders (46)
Institutions that held Upstream Bio, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
Sold out (8)
Institutions that held Upstream Bio, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Ikarian Capital, LLC | 161,113 | $3.03M |
| Balyasny Asset Management LLC | 73,131 | $1.38M |
| Boothbay Fund Management, LLC | 61,299 | $1.15M |
| Nomura Holdings Inc | 28,290 | $532.1K |
| Caption Management, LLC | 18,196 | $342.3K |
| Commonwealth Equity Services, LLC | 15,503 | $292.0K |
| Group One Trading, L.P. | 1,305 | $24.5K |
| Clearstead Advisors, LLC | 163 | $3.07K |